Pentagon responds to WuXi AppTec's lawsuit Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 22 September, 2026

The Endpoints 11 revealed live at the State Room in Boston, plus a fireside chat with the Wyss Institute's Don Ingber and an evening with the founders, scientists and investors behind the list. Reserve your spot with code ELEVEN26. Can't get to Boston? Join us virtually, free.

presented by Every­body op­ti­mizes the first 20% of pa­tient re­cruit­ment. Tri­als fall apart in the oth­er 80%.

news Roche says Carmot-acquired shot delivers Phase 2 win in overweight patients with diabetes Pentagon defends designating WuXi AppTec as Chinese military company  FDA offers little comment on Grail cancer test ahead of adcomm

Sep 22 12:00 pm ET The future of drug pricing: Medicare negotiation, MFN models & beyond sponsored by ADVI Oct 13 11:00 am ET Commercial excellence and AI - a ripple, wave or a tsunami sponsored by ZS Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data sponsored by Natera Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel

Vice President, Regulatory Affairs Hinge Bio, Inc. Redwood City, CA, USA Team Leader, Analytical Research & Development (ARD) Veranova Devens, MA 01434, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

The entire healthcare ecosystem is more Silicon Valley-ified than ever before. What tech has actually changed? Is biopharma behind? Find out, join us for Health Tech day.

Endpoints Pharma Pfizer, Lilly 'most favored nation' deals to give US share of revenue from raised foreign prices Iambic releases next version of its Enchant model, signs deal with AbbVie Telix and radioisotope maker ITM merge in deal worth up to $2.35B

in case you missed it 1. Novo aims to diversify with new pipeline assets and bolt-on deals •  Novo offers low-dose CagriSema data as approval decision looms 2. ADARx targets $319M IPO as TRexBio, Retension join filing queue 3.